Saturday, March 2, 2024

CATEGORY

Servier

FDA Approves Servier’s Tibsovo as First IDH Inhibitor for Myelodysplastic Syndromes

Servier has achieved a milestone as it secures FDA approval for Tibsovo (ivosidenib), making it the first-ever IDH inhibitor authorized for treating myelodysplastic syndromes...

Latest news

Sticky Image